K4l Surfactant Aerosol to Reduce Influenza Lung Injury

Period of Performance: 09/01/2015 - 02/29/2016


Phase 1 SBIR

Recipient Firm

Discovery Laboratories, Inc.
Warrington, PA 18976
Principal Investigator


To support the development of a broadly applicable therapy directed at modulating host factors and immune-mediated processes to reduce lung injury and immunopathology in serious influenza.